News >

Lisocabtagene Maraleucel Elicits Undetectable MRD in Relapsed/Refractory CLL

Nichole Tucker
Published: Tuesday, Aug 06, 2019

Tanya Siddiqi, MD

Tanya Siddiqi, MD

Lisocabtagene maraleucel (liso-cel; JCAR017) led to undetectable minimal residual disease (MRD) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), according to phase I/II results of the TRANSCEND CLL 004 study (NCT03331198).
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication